A study analyzing neutralizing antibody-response of homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants
Latest Information Update: 31 Oct 2022
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; AZD 1222 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 31 Oct 2022 New trial record
- 20 Oct 2022 Results published in the Vaccine